| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(6 years from now) | |
Mayzent is owned by Novartis.
Mayzent contains Siponimod.
Mayzent has a total of 2 drug patents out of which 0 drug patents have expired.
Mayzent was authorised for market use on 26 March, 2019.
Mayzent is available in tablet;oral dosage forms.
Mayzent can be used as a method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose.
Drug patent challenges can be filed against Mayzent from 27 March, 2023.
The generics of Mayzent are possible to be released after 30 November, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 26, 2024 |
| M(M-274) | Mar 01, 2025 |
Drugs and Companies using SIPONIMOD ingredient
NCE-1 date: 27 March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Dosage: TABLET;ORAL
MAYZENT family patents
